Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development
Phase 1 biomarker data shows improvement of safety profiles of vamorolone over prednisolone for adrenal suppression, bone turnover, insulin resistance, and immune suppression. Learn more >
Vamorolone enrollment in Phase 2a opens at Duke University; first DMD subjects enrolled.
microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.
ROCKVILLE, Maryland, March 24, 2017
ReveraGen BioPharma Inc, a privately held corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy. This designation